A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration Sensitive Prostate Cancer (EvoPAR-Prostate01)

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2024
This article has no abstract
Epistemonikos ID: c8f119b75999efa10f2f6b50e1697e49623b09ec
First added on: Apr 12, 2025